Dr. Elena Diez Cecilia is a scientific advisor and the head of commercialization efforts at A2A Pharmaceuticals. A2A leverages proprietary computational systems and machine learning to accelerate development of novel drug alternatives for life threatening diseases with inadequate treatment options, like cancer, bacterial infections and muscular dystrophy.
Elena is a life science innovation specialist with over 8 years of experience in the life sciences in the USA, Canada and Europe, where she contributed to the search for novel therapeutics to treat some of the major diseases concerning society today – Cancer, Neurological and Cardiovascular. Elena has consulted for tier-1 pharmaceutical companies and managed projects for a Venture Capital firm and several innovation organizations across North America.
She earned a Ph.D. from Trinity College Dublin in medicinal chemistry and drug design, followed by a postdoctoral research fellowship at University of Toronto and part-time professorship at San Francisco State University.